Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: a multicentre observational study.
Paret R, Le Bourgeois A, Guillerm G, Tessoulin B, Rezig S, Gastinne T, Couturier MA, Boutoille D, Lecomte R, Ader F, Le Gouill S, Ansart S, Talarmin JP, Gaborit B. Paret R, et al. Among authors: ader f. J Antimicrob Chemother. 2022 Aug 25;77(9):2546-2556. doi: 10.1093/jac/dkac190. J Antimicrob Chemother. 2022. PMID: 35748614
Pristinamycin in the treatment of MSSA bone and joint infection.
Valour F, Boibieux A, Karsenty J, Vallat MP, Braun E, Perpoint T, Biron F, Laurent F, Lustig S, Chidiac C, Ferry T; Lyon Bone and Joint Infection Study Group. Valour F, et al. J Antimicrob Chemother. 2016 Apr;71(4):1063-70. doi: 10.1093/jac/dkv457. Epub 2016 Jan 21. J Antimicrob Chemother. 2016. PMID: 26801082
Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
Benech N, Dumitrescu O, Conrad A, Balsat M, Paubelle E, Ducastelle-Lepretre S, Labussière-Wallet H, Salles G, Cohen S, Goutelle S, Ader F; Lyon HEMINF Study Group. Benech N, et al. Among authors: ader f. J Antimicrob Chemother. 2019 Sep 1;74(9):2676-2680. doi: 10.1093/jac/dkz248. J Antimicrob Chemother. 2019. PMID: 31219562
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B, Vanhove B, Vibet MA, Le Thuaut A, Lacombe K, Dubee V, Ader F, Ferre V, Vicaut E, Orain J, Le Bras M, Omnes A, Berly L, Jobert A, Morineau-Le Houssine P, Botturi K, Josien R, Flet L, Degauque N, Brouard S, Duvaux O, Poinas A, Raffi F; POLYCOR study group. Gaborit B, et al. Among authors: ader f. Trials. 2021 Mar 9;22(1):199. doi: 10.1186/s13063-021-05132-9. Trials. 2021. PMID: 33750432 Free PMC article.
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
Gaborit B, Dailly E, Vanhove B, Josien R, Lacombe K, Dubee V, Ferre V, Brouard S, Ader F, Vibet MA, Le Thuaut A, Danger R, Flet L, Omnes A, Berly L, Chiffoleau A, Jobert A, Duvaux O, Raffi F; POLYCOR Trial Group. Gaborit B, et al. Among authors: ader f. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0123721. doi: 10.1128/AAC.01237-21. Epub 2021 Aug 17. Antimicrob Agents Chemother. 2021. PMID: 34181475 Free PMC article. Clinical Trial.
Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial.
Millon L, Caillot D, Berceanu A, Bretagne S, Lanternier F, Morio F, Letscher-Bru V, Dalle F, Denis B, Alanio A, Boutoille D, Bougnoux ME, Botterel F, Chouaki T, Charbonnier A, Ader F, Dupont D, Bellanger AP, Rocchi S, Scherer E, Gbaguidi-Haore H, Herbrecht R. Millon L, et al. Among authors: ader f. Clin Infect Dis. 2022 Sep 14;75(5):777-785. doi: 10.1093/cid/ciab1066. Clin Infect Dis. 2022. PMID: 34986227 Free article.
Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.
Gaborit B, Vanhove B, Lacombe K, Guimard T, Hocqueloux L, Perrier L, Dubee V, Ferre V, Bressollette C, Josien R, Thuaut AL, Vibet MA, Jobert A, Dailly E, Ader F, Brouard S, Duvaux O, Raffi F; POLYCOR study group. Gaborit B, et al. Among authors: ader f. Open Forum Infect Dis. 2023 Oct 20;10(11):ofad525. doi: 10.1093/ofid/ofad525. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 37942459 Free PMC article.
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
Terzić V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, Peiffer-Smadja N, Mercier N, Delmas C, Ferrane A, Dechanet A, Poissy J, Espérou H, Ader F, Hites M, Andrejak C, Greil R, Paiva JA, Staub T, Tacconelli E, Burdet C, Costagliola D, Mentré F, Yazdanpanah Y, Diallo A; DisCoVeRy Study Group. Terzić V, et al. Among authors: ader f. Clin Infect Dis. 2024 Aug 16;79(2):382-391. doi: 10.1093/cid/ciae170. Clin Infect Dis. 2024. PMID: 38552208 Free PMC article. Clinical Trial.
318 results